ANI PHARMACEUTICALS INC (ANIP) earnings date
Mar 4, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 38 days, typically, give or take 10 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | before open | 36 | 8-K |
| Q2 FY2026 | Fri, Aug 7, 2026 | before open | 38 | 8-K |
| Q1 FY2026 | Fri, May 8, 2026 | before open | 38 | 8-K |
| Q4 FY2025 | Fri, Feb 27, 2026 | before open | 58 | 8-K |
| Q3 FY2025 | Fri, Nov 7, 2025 | before open | 38 | 8-K |
| Q2 FY2025 | Fri, Aug 8, 2025 | before open | 39 | 8-K |
| Q1 FY2025 | Fri, May 9, 2025 | before open | 39 | 8-K |
| Q4 FY2024 | Fri, Feb 28, 2025 | before open | 59 | 8-K |
What they guided beta
| Q3 FY2026 | "Narrows 2026 total company revenue guidance to $1,085 - $1,125 million, revises Cortrophin Gel revenue guidance to $480 - $500 million and raises both adjusted non-GAAP EBITDA to $290 - $300 million, and adjusted non-GAAP diluted earnings per share to $9.37 to $9.71" exhibit |
| Q3 FY2026 | "“As we head into the end of the year, we are focused on delivering our 2026 financial guidance and advancing the proposed acquisition of Egetis toward closing." exhibit |
| Q3 FY2026 | "The acceptance period in the offer is expected to commence on or around November 20, 2026 and to expire on or around December 18, 2026." exhibit |
| Q3 FY2026 | "Full Year 2026 Financial Guidance Revised Full Year 2026 Guidance Previous Full Year 2026 Guidance 2025 Actual Growth Net Revenue (Total Company) $1,085 million - $1,125 million $1,080 million - $1,140 million $883 million 23% - 27% Cortrophin Gel Net Revenue $480 million - $500 million $520 million - $540 million $348 million 38% - 44% ILUVIEN Net Revenue $80 million - $85 million $78 million - $83 million $75 million 7% - 14% Adjusted Non-GAAP EBITDA $290 million - $300 million $285 million - $300 million $230 million 26% - 31% Adjusted Non-GAAP Diluted EPS $9.37 - $9.71 $9.19 - $9.69 $7.89 " exhibit |
| Q3 FY2026 | "ANI is not providing a reconciliation for the forward-looking full year 2026 adjusted non-GAAP EBITDA guidance because it does not currently have sufficient information to accurately estimate all of the variables and individual adjustments for such reconciliation, including “with” and “without” tax provision information." exhibit |
| Q2 FY2026 | "Reaffirming 2026 guidance for total net revenue of $1,080 - $1,140 million and adjusted non-GAAP EBITDA of $285 - $300 million PRINCETON, N.J., August 7, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the second quarter ended June 30, 2026." exhibit |
| Q2 FY2026 | "“We are reaffirming our full year 2026 total net revenue guidance of $1,080 - $1,140 million and adjusted non-GAAP EBITDA of $285 - $300 million." exhibit |
| Q2 FY2026 | "Based on our results in the first half of 2026, we are modestly adjusting our Cortrophin Gel net revenue guidance to $520 - $540 million, reflecting 50-55% growth for the full year." exhibit |
| Q2 FY2026 | "The Company announced 6-month topline data from the Phase 4 open-label single-arm SYNCHRONICITY clinical trial in chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) and anticipates announcing the detailed results and additional analyses at a key medical conference attended by retina specialists in the fourth quarter of 2026." exhibit |
| Q2 FY2026 | "The balance of the development work is expected to be completed in the third quarter of 2026, at which time the Company will recognize an additional $2.0 million in development milestone revenue." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/ANIP
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/ANIP
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/ANIP/"><img src="https://veritasdata.dev/embed/ANIP.svg" alt="ANIP earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/ANIP/)
Script
<script async src="https://veritasdata.dev/embed/ANIP.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/ANIP"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.